TableĀ 5

Beliefs about current practice, facilitators and barriers to the non-pharmaceutical management of LVSD and HFpEF (selected questions)

Management issueGPCardiologistGeneral physicianHF nurseAll respondents
N=251N=103N=54N=78N=494
Access to an HF clinic150 (59.8%)83 (80.6%)36 (66.7%)69 (88.5%)338 (68.4%)
Routinely refer to an HF clinic103 (41.0%)65 (63.1%)35 (64.8%)66 (84.5%)269 (54.5%)
Access to HF rehabilitation126 (50.2%)63 (61.2%)24 (44.4%)57 (73.1%)270 (54.7%)
Access to electrical therapies for HF172 (68.5%)103 (100%)42 (77.8%)78 (100%)395 (80.0%)
Access to end-of-life care pathway for HF181 (72.1%)84 (81.6%)31 (57.4%)69 (88.5%)365 (73.9%)
Responsible for end-of-life care for HF194 (77.3%)35 (34.0%)17 (31.5%)61 (78.2%)307 (62.1%)
  • GP, general practitioner; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; LVSD, left ventricular systolic dysfunction.